Investors shrug off drug price talks' effects

Unless you were under a rock, you saw Thursday's news that Medicare negotiated a better deal than the private market for some of the program's top-selling drugs.

Why it matters: So what? How meaningful is that difference, and what will the longer-term effects be?

Some seniors will likely pay less out of pocket for drugs (that's a whole different topic), and that obviously matters to patients. But how pharma interprets the negotiated prices and reacts to them will have a huge impact on future drug development.